Company intelligence / Profile preview

Gylden Pharma

Abingdon, Oxfordshire, United Kingdomlinkedin.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 2

Overview

Gylden has demonstrated safety and proof-of-concept in first-in-human trials with its synthetic T cell–priming vaccine candidates against dengue and betacoronavirus. The gold nanoparticle platform enables robust CD8+ T cell responses with long-lasting immunity. Multiple programs are advancing toward or in early clinical development targeting high-priority infectious diseases.

Therapeutic areas: Infectious Diseases
Modalities: Synthetic peptide vaccinesGold nanoparticle-based delivery systemsMicroneedle array patches
Industry: Biotech

Drug pipeline

9 assets

PepGNP-COVID19

8 more assets in the full pipeline.

Request access →

Partnerships

Strategic partnerships with government health authorities for pandemic preparedness and public health response; business development opportunities with national/regional biopharmas are ongoing. Specific partners not named.

Beyond the preview

Go deeper on Gylden Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gylden Pharma.

Explore the full profile